N

Start-ups · Healthtech & Bio

Nanoligent

www.nanoligent.com ↗ ·Barcelona ·Series A

Nanoligent is a Barcelona-based biotechnology company developing targeted nanodrugs for cancer treatment, combining protein engineering and nanobiotechnology to deliver therapies selectively to tumour cells with fewer side effects than conventional drugs. Its lead candidate, NNL1524, targets the CXCR4 receptor, which is overexpressed in more than 20 cancer types including colorectal, lung and breast cancer, acute myeloid leukaemia and diffuse large B-cell lymphoma, and is moving from regulatory preclinical development into a Phase Ia study in patients with solid tumours. The company was founded in 2017 as a spin-off of the Universitat Autònoma de Barcelona and the Research Institute of Hospital de la Santa Creu i Sant Pau, and is based at the UAB campus in Bellaterra. In February 2022 it closed a €1M seed round led by members of Italian Angels for Growth and Avanteca Partners, and in October 2025 it raised €12M in a round led by Inveready Biotech IV with participation from CDTI's Innvierte programme, Clave Capital's Clave Innohealth fund and existing investors i&i Biotech Fund I, Italian Angels for Growth and Avanteca.

Suggest a correction